Vancouver, BC, Canada, November 6, 2013 - Auxellence Health Corporation (CNSX:AID) (the "Issuer" or "Auxellence") and Mr. Sydney Au, President and CEO of the company, announce as a result the closing of the Private Placement Offering of the issuance of 1,040,000 shares at $0.20 and the concurrent closing of the Convertible Debentures for Shares convertible at $0.20; and with Mr. Au's private company, 918368 BC Ltd. participating in the Convertible Debenture for Common Shares at $0.20 by converting various cash loans totaling $238,500 to the Issuer into the Convertible Debenture, Mr. Au's holdings of the Issuer post closing of the Private Placement and Convertible Debentures will be as follows: Direct personal holdings will remain at 18,500,000 shares (down to 43.61% from 44.71%) of the Issuer and his private company will remain holding 12,500,000 shares (down to 29.47% from 30.21%) of the Issuer along with his private company holding a Convertible Debenture that can be converted into 1,192,500 shares (2.81% of the 42,417,684 shares issued and outstanding post closing of the Private Placement) of the Issuer at $0.20. Therefore should Mr. Au exercise the right to convert 918368BC's Convertible Debenture or be required to convert by the company, Mr. Au's maximum number of shares under his control would be as follows: From Mr. Au's personal holdings 18,500,000 shares (42.421% down from 44.71%) and his company "918368BC" would hold 13,692,500 shares (31.397% up from 30.21%) of the 43,610,184 shares then issued and outstanding. Mr. Au's total maximum control of shares of the company will be down to 73.819% of the total (43,610,184) issued and outstanding shares in the company (post issuance of the shares for 918368BC's Convertible Debenture) from his original maximum total control of shares of 74.919% of the total (41,377,684) originally issued and outstanding shares in the company (prior to the Private Placement Offering and prior to any issuance of the shares for the Issuer's Convertible Debenture or any currently outstanding options).
For further information and to obtain a copy of the early warning report filed under applicable Canadian and provincial securities legislation in connection with the transaction hereunder please see the Issuer's profile on SEDAR at http://www.sedar.com/.
Contact:
Sydney Au, President & CEO or Ronald Ozols, Director
Auxellence Health Corporation
Email: [email protected]; [email protected]
Phone: (604) 780-3311
About Auxellence Health Corporation
Auxellence is a health technology company that aims to provide high-level online services to consumers, providers and suppliers of health care products and services, including refining the effectiveness of prescribing services to the Over-The-Counter (OTC) consumer and natural health industry. Integrating innovative therapeutic and diagnostic (theragnostic) devices (hardware components), along with an interactive Expert System and Recommender "PRESCRIPTOR" engine (software platform) the system acquires physiological data to offer personalized health solutions to everyday common health issues (initially targeting weight management and skin health-acne).
Disclaimer for Forward-Looking Information Statements in this press release regarding the Company which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as "may", "will", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. Except as required by law, the Company does not intend to update any changes to such statements. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither CNSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CNSX) accepts responsibility for the adequacy or accuracy of this release.
THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES